Q3 2023 · 13F-HR
Commodore Capital LPholdings as filed
Filed 2023-11-14 · accession 0001831942-23-000011
$855.5M
Reported value
30
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N5749R100 | 2GH | MERUS N V | $104.4M | 12.2% | 4,428,072 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $74.7M | 8.73% | 5,450,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $63.0M | 7.37% | 1,845,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $56.1M | 6.55% | 1,100,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $54.3M | 6.34% | 5,566,026 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $47.6M | 5.56% | 2,075,000 | Common | SOLE |
| 02290A102 | — | AMBRX BIOPHARMA INC | $40.5M | 4.73% | 3,518,556 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $39.6M | 4.63% | 2,901,816 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $38.4M | 4.49% | 2,525,753 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $38.4M | 4.49% | 1,000,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $38.1M | 4.45% | 828,778 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $33.7M | 3.94% | 2,200,000 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $28.6M | 3.34% | 565,000 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $26.2M | 3.06% | 887,500 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $20.9M | 2.44% | 775,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $19.4M | 2.27% | 706,665 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $15.5M | 1.81% | 1,694,141 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $15.2M | 1.77% | 1,325,000 | Common | SOLE |
| 00773U108 | ADVMCHF | ADVERUM BIOTECHNOLOGIES INC | $15.0M | 1.75% | 10,000,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $14.9M | 1.74% | 500,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $13.9M | 1.63% | 957,509 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $12.8M | 1.49% | 1,400,000 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $10.9M | 1.27% | 1,700,000 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $9.1M | 1.06% | 739,661 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $8.3M | 0.96% | 1,575,000 | Common | SOLE |
| 75525N107 | — | RAYZEBIO INC | $6.4M | 0.75% | 288,911 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $5.3M | 0.62% | 250,000 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $2.9M | 0.33% | 2,244,378 | Common | SOLE |
| 00773J202 | SYRE | AEGLEA BIOTHERAPEUTICS INC | $1.4M | 0.17% | 116,324 | Common | SOLE |
| 23306J101 | — | DBV TECHNOLOGIES S A | $126,054 | 0.01% | 92,687 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.